Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

DRSI Launches The First And Only Diabetes Energy Formula Specifically Created For Diabetics To Counter Their No. 1 Complaint: Fatigue
Diabetica Research Solutions, Inc. (DRSI) http://www.drsirestoreenergy.com: Diabetes is a disease of energy currently affecting 24 million people who have been diagnosed and approximately 55 million who are in a pre-diabetic condition. For so many of these people with diabetes, particularly those with type 2 diabetes, persistent fatigue is a constant complaint. According to a 2007 survey of 8,000 people with diabetes, approximately 85% of respondents reported that fatigue was their number one complaint. When asked how they dealt with their fatigue, 17% of respondents said they do nothing, 31% drink water, 23% drink coffee, 6% drink energy drinks and 23% drink sodas and diet sodas. Now, with the introduction of drsi™ Restore! Energy, there"s a quick and effective way for diabetics and pre-diabetics to experience balanced, long lasting energy and stamina to help them through their daily routines.
generic viagra online
Schizophrenia Linked For First Time To Chromosome Region In Study Led By Stanford Scientists
Stanford University School of Medicine scientists have played a major role in an international effort that has shown, for the first time, that modern genetic technologies can solve the riddle of how gene variations lead to schizophrenia.
News of the day
Positive Long-Term Data For BENLYSTA (formerly LYMPHOSTAT-B(R)) In Patients With Active Lupus
Human Genome Sciences (HGS) has reported continuation data from a Phase II study of BENLYSTA™ (belimumab, formerly LymphoStat-B®) showing sustained improvement in patients with active systemic lupus after four years of treatment. The data was presented at the EULAR 2009 scientific meeting in Copenhagen, Denmark.
Diagnostics

Foresight Biotherapeutics Announces Positive Results From An Open Label Pilot Study In Patients With Viral Conjunctivitis

Foresight Biotherapeutics, Inc. announced completion of a multi-center open-label pilot study of FST100 in the treatment of viral conjunctivitis. FST-100 is a novel formulation of dexamethasone that includes povidone iodine. The trial studied patients with clinical signs and symptoms of acute conjunctivitis who tested positive for adenoviral antigen by the RPS Adeno Detector® (RPS). Patients were enrolled in a single arm utilizing FST-100 topical ophthalmic suspension given 4 times daily for 5 days. The RPS Adeno Detector® test was performed at baseline and at each visit along with conjunctival swabs for adenoviral titers by quantitative PCR (qPCR) and cell culture with confirmatory immunoflourescence (CC-IFA). The primary endpoint of the study was clinical resolution of conjunctival injection and conjunctival discharge. These signs were scored on a scale from zero to three. Secondary endpoints included reduction of viral titers measured by qPCR and eradication of infectious virus determined by CC-IFA. FST-100 met the primary endpoint of the study by demonstrating complete resolution of conjunctivitis signs (a score of zero) in all eyes completing the study. One patient was lost to follow-up. In all RPS positive eyes with confirmed viral infection by qPCR and CC-IFA clinical symptoms resolved within 72 hours. All eyes completing the study with detectable adenovirus by qPCR demonstrated significant reduction in viral titers by 48-96 hours and the majority demonstrated elimination of infectivity by CC-IFA by 72-96 hours. There were no adverse events in the study. Lead investigator Jesse Pelletier, M.D. commented, "We are excited about this preliminary data and look forward to enrolling patients in a larger controlled clinical study. Currently, there are no drugs approved for the treatment of viral conjunctivitis and it is certainly an area of unmet medical need." Foresight Biotherapeutics, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009